Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

被引：0
|
作者：
Jason D. Lickliter
Mark Voskoboynik
Linda Mileshkin
Hui K. Gan
Ganessan Kichenadasse
Kathy Zhang
Maggie Zhang
Zhiyu Tang
Michael Millward
机构：
[1] Nucleus Network,Department of Medicine
[2] Central Clinical School,undefined
[3] Monash University,undefined
[4] Peter MacCallum Cancer Centre-East Melbourne,undefined
[5] Olivia Newton-John Cancer Wellness and Research Centre,undefined
[6] Austin Hospital,undefined
[7] Heidelberg,undefined
[8] La Trobe University School of Cancer Medicine,undefined
[9] University of Melbourne,undefined
[10] Flinders Centre for Innovation in Cancer,undefined
[11] Flinders Medical Centre,undefined
[12] BeiGene USA,undefined
[13] Inc.,undefined
[14] Linear Clinical Research & University of Western Australia,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 585
页数：9
相关论文
共 50 条
  • [41] A Phase 1b Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0941 in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Lolkema, M.
    Leong, S.
    Voest, E.
    Freas, E.
    Shankar, G.
    Brachmann, R. K.
    Moss, R. A.
    Stein, M. N.
    Mergui-Roelvink, M.
    Schellens, J. H. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 111 - 112
  • [42] A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Couillault, Coline A.
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina E.
    Yap, Timothy A.
    Subbiah, Vivek
    Bhosale, Priya
    Coarfa, Cristian
    Higgins, Jack P.
    Williams, Eric T.
    Wilson, Thomas F.
    Lim, JoAnn
    Meric-Bernstam, Funda
    Sumner, Elizabeth
    Zain, Hira
    Di Nguyen
    Nguyen, Ly M.
    Rajapakshe, Kimal
    Curran, Michael A.
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2021, 27 (11) : 3050 - 3060
  • [43] A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors
    Leong, Stephen
    Moss, Rebecca A.
    Bowles, Daniel W.
    Ware, Joseph A.
    Zhou, Jing
    Spoerke, Jill M.
    Lackner, Mark R.
    Shankar, Geetha
    Schutzman, Jennifer L.
    van der Noll, Ruud
    Voest, Emile E.
    Schellens, Jan H. M.
    ONCOLOGIST, 2017, 22 (12): : 1491 - 1499
  • [44] A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma
    Gong, Jifang
    Guo, Ye
    Zhang, Yanqiao
    Ba, Yi
    Chen, Tong
    Li, Wei
    Zhou, Caicun
    Wang, Mengzhao
    Yang, Haiyan
    Zhou, Yuhong
    Cai, Qiqing
    Wang, Ziping
    Huang, Gang
    Zhang, Wei
    Su, Rila
    Cai, Zhongheng
    Yue, Zenglian
    Dou, Jinzhou
    Li, Peiqi
    Wu, Rachel
    Tse, Archie N.
    Shen, Lin
    TARGETED ONCOLOGY, 2024, 19 (05) : 723 - 733
  • [45] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Toshihiko Doi
    Narikazu Boku
    Yusuke Onozawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Atsushi Ohtsu
    Investigational New Drugs, 2020, 38 : 1390 - 1399
  • [46] Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study
    Ji, Dongmei
    Shen, Weina
    Li, Ting
    Wang, Huan
    Bai, Jianling
    Cao, Junning
    Hu, Xichun
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 462 - 470
  • [47] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Doi, Toshihiko
    Boku, Narikazu
    Onozawa, Yusuke
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1390 - 1399
  • [48] Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic solid tumors
    Stradella, Agostina
    Johnson, Melissa
    Goel, Sanjay
    Park, Haeseong
    Lakhani, Nehal
    Arkenau, Hendrik-Tobias
    Galsky, Matthew D.
    Calvo, Emiliano
    Baz, Vicente
    Moreno, Victor
    Saavedra, Omar
    Luen, Stephen J.
    Mu, Song
    Wan, Qiting
    Chang, Victoria
    Zhang, Wa
    Barve, Minal
    CANCER MEDICINE, 2024, 13 (13):
  • [49] A Phase 1b study to evaluate the safety and antitumor activity of MEDI4736 in combination with tremelimumab in patients with advanced NSCLC
    Goldberg, S. B.
    Balmanoukian, A.
    Chaft, J.
    Rizvi, N.
    Sanborn, R. E.
    Rebelatto, M. C.
    Narwal, R.
    Robbins, P. B.
    Gu, Y.
    Karakunnel, J. J.
    Antonia, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S627 - S627
  • [50] A phase 1 dose escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies
    Hegde, Aparna
    Jayaprakash, Priyamvada
    Sumner, Elizabeth
    Di Nguyen
    Zain, Hira
    Piha-Paul, Sarina
    Karp, Daniel
    Rodon, Jordi
    Pant, Shubham
    Fu, Siqing
    Dumbrava, Ecaterina
    Yap, Timothy
    Subbiah, Vivek
    Bhosale, Priya
    Higgins, Jack
    Williams, Eric T.
    Wilson, Thomas F.
    Meric-Bernstam, Funda
    Curran, Michael
    Hong, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345